Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19, is ...

Boston-based Moderna has been the S&P 500’s most shorted stock since the end of September, according to S3 Partners. Short ...

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, ...

Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This ...

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00 in a research note issued on Friday,Benzinga reports. The firm ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...